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ABSTRACT 
The synthesis of N1 and N2 coumarin substituted 1,2,3-triazole isomers 
from terminal alkynes, sodium azide, and 4-bromomethylcoumarins in 
the presence of triethylamine as a base and CuI as a catalyst in good 
yield are reported. The molecular structure of compounds 3g and 5d 
are established by single-crystal analysis.  
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Introduction 
Sharpless established the concept of click chemistry, which has been exploited as a 
powerful tool for the development and discovery of drugs. A click reaction consists of 
readily available reactants and reagents as well as simple reaction conditions and purifi-
cation process. Click reactions must furnish good yields and stable products under 
physiological conditions. Of the reactions in the click universe, the perfect example is 
the Huisgen 1,3-dipolar cycloaddition of alkynes to azides to form N1 substituted 
1,2,3-triazoles.[1] 
The synthesis of 1,2,3-triazoles is an important synthetic reaction as these scaffolds are 
found to form a very important core in numerous synthetic, pharmaceuticals, and a wide 
variety of biologically active compounds.[2] A large number of compounds bearing 1,2,3- 
triazole scaffolds have entered preclinical and clinical trials over the past few years. Some 
commercially available 1,2,3-triazole drugs[3] (Fig. 1) including bazel (antiepileptic drug), 
tazocin ef (antibiotic for community-acquired pneumonia caused by Pseudomonas aerugi-
nosa), and suvorexant (brain penetrant dual orexin receptor antagonist) are derived from 
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triazole core entities. 1,2,3-Triazole structure moieties also exhibited antibacterial,[4] 
antiprotozoal,[5] antifungal,[6] antioxidant,[7] antitubercular,[8] and anticancer[9] activities. 
Coumarins are known to be biologically versatile compounds possessing several biological 
properties.[10] It has been reported that coumarin compounds bearing other heterocyclic 
systems possess a number of interesting biological activities such as antitumor,[11] antiox-
idant,[12] anti-ischemic,[13] and anticancer[14] activities. Based on the survey of recent 
literature studies on triazoles and coumarins, the aim of our work is synthesis of 
triazolylcoumarins. 
The synthesis of 1,2,3-triazoles has evoked much attention, and a variety of synthetic 
methodologies have been reported.[15–17] However, these methods have limitations as they 
produce mainly N1 substituted 1,2,3-triazole isomer but not N2 substituted 1,2,3-triazole 
isomer. Many methods for the synthesis of N2 substituted 1,2,3-triazole isomer have been 
reported in the past few years. The most important approaches are (i) Mitsunobu reaction 
of NH-triazoles with alcohols,[18] (ii) Cu(II)-catalyzed aerobic oxidation of bis arylhydra-
zones,[19] (iii) Ullman-type Cu(I)I-catalyzed amination of 1,2,3-triazole,[20] (iv) Chen’s 
synthesis of N-2-aryl-1,2,3-triazole,[21] (v) from allylcarbonate, alkynes, and TMSN3,[22] 
(vi) from chalcones and NaN3 using Fe2O3 nanoparticles as catalyst,[23] (vii) regioselective 
N-2-substituted-1,2,3-triazoles with electrophiles,[24] (viii) N-2 selective palladium- 
catalyzed arylation of 1,2,3-triazoles,[25] (ix) from 2-arylhydrazononitriles and hydroxyl 
amine.[26] However, these methods have certain drawbacks as they involve tedious experi-
mental procedures such as refluxing the reaction mixture at high temperature for long 
hours. It is, therefore, necessary to develop synthesis of N2 substituted 1,2,3-triazole isomer 
at ambient temperature. 
In recent years, copper(I) iodide has proved to be a very useful catalyst[27] in carrying 
out multicomponent synthesis of heterocycles such as triazoles,[28] benzoxazoles,[29] and 
pyrrolidines.[30] Copper(I) iodide has received increasing attention as an inexpensive, 
nontoxic, and readily available catalyst for organic synthesis. Copper(I) iodide has high tol-
erance to moisture as well as air, making it an ideal catalyst. It can be easily removed from 
the reaction mixture by quenching[31] and washing with water. The use of copper(I) iodide 
as a catalyst is not only cost-effective and regioselective and environmentally benign but 
also experimentally simple, easy to handle, and safe.[32] 
Figure 1. Commercially available triazole drugs.  
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Herein, we report the synthesis of N1 and N2 coumarin substituted 1,2,3-triazole isomers 
by the reaction of terminal alkynes, sodium azide, and 4-bromomethylcoumarins in the 
presence of copper(I) iodide as a catalyst and Et3N as a base in one pot at ambient 
temperature under aerobic condition in good yields. 
Results and discussion 
4-Bromomethylcoumarins[33] 2(a–i) were synthesized by Pechmann cyclization of 
substituted phenols with 4-bromoethylacetoacetate[34] using concentrated H2SO4 as a con-
densing agent. First the optimization of the reaction was studied, for which the reaction of 
4-bromomethyl-6-methylcoumarin, sodium azide, and propargyl alcohol was selected as a 
model (Scheme 1). It is known that a copper(I) iodide in the presence of triethylamine 
catalyzed the one-step fusion of N2 coumarin substituted 1,2,3-triazole by forming a better 
activated intermediate. A preliminary examination showed that copper(I) iodide in the 
presence of triethylamine in acetone among several solvents catalyzed the model reaction 
at room temperature. Of the reactions using different quantities of reactant, the best results 
were obtained by using a 1.2:1.0:1.0 ratio of sodium azide, propargyl alcohol, and 4- 
bromomethyl-6-methylcoumarin. 
A mixture of sodium azide, propargyl alcohol, copper(I) iodide, and triethylamine in 
acetone was stirred for an hour at room temperature. 4-Bromomethyl-6-methylcoumarin 
was added and the stirring was continued for another 8 h. 4-((4-(Hydroxymethyl)-2H- 
1,2,3-triazol-2-yl)methyl)-6-methyl-2H-chromen-2-one (3a) was obtained in excellent 
yield (96%). If 4-bromomethyl-6-methylcoumarin was taken first, followed by adding 
sodium azide and alkyne, then N1 coumarin substituted 1,2,3-triazole (5a) would be the 
product[35] (Scheme 2). 
Decreasing the amount of catalyst from 10 mol% to 5 mol% lowered the N2 coumarin 
substituted 1,2,3-triazole yield (65%) while increasing the amount of catalyst from 
10 mol%  to 20 mol% did not shown any significant impact on the N2 coumarin substi-
tuted 1,2,3-triazole yield, indicating that this reaction condition was suitable for the 
one-pot assembly. 
The role of solvents on the synthesis of N2 coumarin substituted 1,2,3-triazole (3a) 
was then studied and the results are depicted in Table 1. Replacing the acetone by 
Scheme 1. Synthesis of N2 coumarin substituted 1,2,3-triazoles.  
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acetonitrile produced the model in an appreciable yield (entry 3), albeit less than that 
produced by the former (entry 4). Other solvents such as ethanol, CHCl3, dimethylfor-
mamide (DMF), and dimethylsulfoxide (DMSO) accomplished the model in moderate 
yields (56–72%, entries 1, 2, 5, and 6), while aqueous solvents including mixture of 
water with acetone, acetonitrile, and DMSO produced still lower yields (34–48%, 
entries 7, 8, and 9). 
Optimized condition was established in acetone as a solvent system at room temperature 
for 9 h. This remarkable activation in reaction rate prompted us to explore the potential of 
this protocol for the synthesis of a variety of N2 coumarin substituted 1,2,3-triazoles. All 
the aforementioned reactions proceeded expeditiously and delivered better to excellent 
product yields. The overall yield ranged from 96%  of 4-((4-(hydroxymethyl)-2H- 
1,2,3-triazol-2-yl)methyl)-6-methyl-2H-chromen-2-one (3a) to 85%  of 6-chloro-4- 
((4-(hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-2H-chromen-2-one (3i). 
A probable mechanistic pathway for the formation of N2 coumarin substituted 1,2,3- 
triazoles is outlined (Fig. 2), which is in analogy to the established mechanism as reported 
in the literature.[36] The copper(I) species formed a pi complex with the triple bond of a 
terminal alkynes. In the presence of a base, the terminal hydrogen, being the most acidic, 
is deprotonated first to give a copper acetylide intermediate. Subsequent 1,3-dipolar 
cycloaddition with sodium azide produced 1,2,3-triazole anions that attacked 4- 
bromomethylcoumarins to give N2 coumarin substituted 1,2,3-triazoles. 
Table 1. Optimization of solvents at room temperature for the synthesis (3a). 
Entry Solvent Time (h) Yield (%)  
1 Ethanol 9 72 
2 Chloroform 10 56 
3 Acetonitrile 8 83 
4 Acetone 9 96 
5 DMF 10 60 
6 DMSO 10 65 
7 Acetone/H2O (1:1) 11 48 
8 Acetonitrile/H2O (1:1) 11 34 
9 DMSO/H2O (1:1) 12 42  
Scheme 2. Synthesis of N1 coumarin substituted 1,2,3-triazoles.  
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Conclusion 
In conclusion, we have developed a simple and one-pot procedure for the synthesis of N1 
and N2 coumarin substituted 1,2,3-triazole isomers from terminal alkynes, sodium azide, 
and 4-bromomethylcoumarins in the presence of copper(I) iodide as a catalyst and triethy-
lamine as a base at ambient temperature in the aerobic condition in encouraging yields. 
Experimental 
The melting points were determined by open capillary method using an electric melting- 
point apparatus and are uncorrected. The IR spectra (KBr disc) were recorded on 
a Shimadzu-8400S FT-IR spectrophotometer. 1H NMR (400 MHz) and 13C NMR 
(100 MHz) were recorded on a Bruker spectrometer by using CDCl3/DMSO-d6 as a 
solvent and tetramethylsilane (TMS) as an internal standard. The chemical shifts are 
expressed in δ parts per million (ppm). The high-resolution mass spectrum (HRMS) 
was recorded at IISC, Bangalore. The purity of the compound was checked by thin-layer 
chromatography (TLC). The elemental analyses were carried out using Elemental Vario 
Micro Cube CHN rapid analyzer. All the compounds gave satisfactory elemental analysis. 
The molecular structure of the compounds 3g and 5d are established by single-crystal 
x-ray analysis[37,38] (Figs. 3 and 4). 
General procedure for the synthesis of 4-((4-(hydroxymethyl)-2H-1,2,3-triazol-2- 
yl)methyl)-6-methyl-2H-chromen-2-one (3a) 
A mixture of propargyl alcohol (0.11 g, 1.9 mmol), sodium azide (0.14 g, 2.0 mmol), copper 
(I) iodide (10 mol%), and triethylamine (0.19 g, 1.9 mmol) in 20 ml of acetone was taken in 
a round-bottom flask and stirred for an hour. To this, 4-bromomethyl-6-methylcoumarin 
(0.5 g, 1.9 mmol) was added, and the stirring was continued for 8 h (the reaction was 
monitored by TLC). After the completion of the reaction, the catalyst was filtered through 
celite and the product was extracted with ether (3 � 10 ml). The solvent was removed under 
vacuum. The crude product was dried and recrystallized from ethyl acetate. 
Figure 2. Plausible reaction mechanism for the synthesis of N2 coumarin substituted 1,2,3-triazoles.  
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4-((4-(Hydroxymethyl)-2H-1,2,3-triazol-2-yl)methyl)-6-methyl-2H-chromen- 
2-one (3a) 
Yield 96%; colorless solid; mp 188–191 °C; IR (KBr, cm  1): 1772 cm  1(lactone C=O), 
3238 cm  1(OH); 1H NMR (400 MHz, CDCl3): δ 2.17 (s, 1H, OH), 2.42 (s, 3H, C6-CH3) 
4.85 (s, 2H, -CH2O-), 5.72 (s, 2H, -CH2N-), 5.99 (s, 1H, C3-H), 7.29 (m, 1H, C7-H), 
7.39 (m, 2H, C8-H & C5-H), 7.61 (s, 1H, Tr-H) ppm. 13C NMR (100 MHz, DMSO-d6): 
δ 20.4, 48.9, 55.0, 113.3, 116.5, 123.8, 124.6, 133.3, 133.8, 148.6, 149.7, 150.4, 151.1, 
159.0 ppm. Anal. calcd. for C14H13N3O3: C, 61.99; H, 4.83; N, 15.49. Found: C, 61.94; H, 
4.80; N, 15.43. 
Figure 3. ORTEP diagram of the molecule 3g at 40% probability.  
Figure 4. ORTEP diagram of the molecule 5d at 50% probability.  
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General procedure for the synthesis of 4-(azidomethyl)-6-ethyl-2H-chromen-2- 
one (4b)[39,40] 
4-Bromomethyl-6-ethylcoumarin (0.5 g, 0.001 mol) was taken in 15 ml acetone in a 
round-bottomed flask. To this, sodium azide (0.12 g, 0.001 mol) in 5 ml of water was added 
dropwise with stirring, which was continued for 3 h (the reaction was monitored by TLC). 
The reaction mixture was poured into ice-cold water, and the separated solid was filtered 
and recrystallized from ethyl acetate. 
4-(Azidomethyl)-6-ethyl-2H-chromen-2-one (4b) 
Yield 88%; colorless solid; mp 105–107 °C; IR (KBr, cm  1): 1719 cm  1(lactone C=O), 
2120 cm  1(N3); 1H NMR (400 MHz, CDCl3): δ 1.23 (t, 3H, CH3 of C2H5 group, J1,2 ¼ 7.6  
Hz), 2.68 (q, 2H, CH2 of C2H5 group, J1,2 ¼ 7.6 Hz), 4.73 (s, 2H, -CH2N-), 6.28 (s, 1H, 
C3-H), 7.30 (d, 1H, C7-H, J1,2 ¼ 8.4 Hz), 7.35 (d, 1H, C8-H, J1,2 ¼ 8.4 Hz), 7.40 (s, 1H, 
C5-H) ppm. 13C NMR (100 MHz, DMSO-d6): δ 16.9, 25.6, 53.2, 113.3, 116.3, 121.0, 
123.5, 133.6, 134.7, 148.6, 150.3, 160.8 ppm. Anal. calcd. for C12H11N3O2: C, 62.87; H, 
4.84; N, 18.33. Found: C, 62.79; H, 4.71; N, 18.23. 
General procedure for the synthesis of 4-((4-(hydroxymethyl)-1H-1,2,3-triazol-1- 
yl)methyl)-6-methyl-2H-chromen-2-one (5a) 
To a solution of propargyl alcohol (0.11 g, 1.9 mmol) in acetone, CuI (10 mol%) and 
triethylamine (0.19 g, 1.9 mmol) were added. The mixture was stirred at room tem-
perature for 15 min. Then, 4-(azidomethyl)-6-methyl-2H-chromen-2-one (0.42 g, 
1.9 mmol) was added and resulting mixture was stirred until the starting material 
was consumed as judged by TLC. After the completion of the reaction, the catalyst 
was filtered through celite and the product was extracted with ether (3 � 10 ml). 
The solvent was removed under vacuum. The crude product was dried and recrystal-
lized from ethyl acetate. 
4-((4-(Hydroxymethyl)-1H-1,2,3-triazol-1-yl)methyl)-6-methyl-2H-chromen-2- 
one (5a) 
Yield 90%; colorless solid; mp 224–226 °C; IR (KBr, cm  1): 1714 cm  1(lactone C=O), 
3228 cm  1(OH); 1H NMR (400 MHz, CDCl3): δ 1.80 (s, 1H, OH), 2.45 (s, 3H, C6-CH3) 
5.08 (s, 2H, -CH2O-), 5.92 (s, 2H, -CH2N-), 6.19 (s, 1H, C3-H), 7.29–7.44 (m, 3H, 
Ar-H), 8.23 (s, 1H, Tr-H) ppm. 13C NMR (100 MHz, DMSO-d6): δ 21.3, 50.8, 56.7, 
104.5, 112.6, 114.5, 116.6, 117.0, 119.6, 129.9, 147.6, 148.7, 151.8, 160.4 ppm. Anal. calcd. 
for C14H13N3O3: C, 61.99; H, 4.83; N, 15.49. Found: C, 61.95; H, 4.80; N, 15.39. 
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